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petition between brand-name and generic drugs was observed in
the US Medicaid marketplace.
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IMPACT OF RELABELING ON NEFAZODONE PRESCRIBING:
A RISK MINIMIZATION EVALUATION
Morrato EH,Valuck RJ
University of Colorado, Denver, CO, USA
OBJECTIVE: In 2002, FDA added a boxed warning to the label-
ing of the antidepressant nefazodone describing its association
with acute liver failure and recommending liver function testing.
The aim of this study was to assess the impact of relabeling on
nefazodone utilization in community practice. METHODS: 
De-identiﬁed prescription claims from PharMetrics, a US medical
claims database vendor, were evaluated 45 months pre and 21-
months post relabeling for patients with ≥1 nefazodone claim
and ≥90 days enrollment history. The average number of unique
prescribers and total (TRx) and new-use (NRx) nefazodone pre-
scriptions were calculated by quarter and stratiﬁed by physician
specialty: primary care (PCP) (general practitioner, family prac-
titioner, internist) vs. psychiatry. New-use was deﬁned as the ﬁrst
nefazodone prescription. Changes in prescribing trends were
evaluated with t-tests (unequal variance). RESULTS: Relabeling
caused a pronounced reversal in TRx prescribing trends (p <
0.001). Prior to relabeling, TRx’s increased 5,676 Rx/quarter
(95% CI: 4592–6760) peaking at 30,688 (October–December,
2001). Immediately following relabeling, TRx’s dropped 28% 
to 21,994 (January–March, 2002) with a sustained decrease of
13, 582 TRx/quarter (95% CI: 8646–18,518) on average
through July–September, 2003. A similar signiﬁcant reversal was
also seen for NRx’s (p < 0.001). PCP prescribing was more 
sensitive to relabeling than psychiatrist prescribing with an
average reversal in prescribing trends of 7542 TRx’s /quarter
(95% CI: 7125–7959) for PCP’s compared to 336 TRx’s/quarter
(95% CI: 291–381). The number of unique nefazodone pre-
scribers also changed (p < 0.001) reversing from an average
increase of 1890/quarter (95% CI: 567–2213) prior to relabel-
ing to a decrease of 3209/quarter (95% CI: 1833–4585). CON-
CLUSION: The ﬁndings indicate added nefazodone safety
warnings had an immediate and sustained impact in decreasing
prescribing. While fewer patients appear at risk from nefazodone
liver toxicity following relabeling, further studies are needed to
determine whether liver enzyme monitoring practices also
changed.
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PRESCRIBING OF ANTIDEPRESSANTS
Tan H1, Lin SJ2, Lambert BL3, Sclove SL3
1HealthCore, Wilmington, DE, USA; 2University of Illinois, Chicago, IL,
USA; 3University of Illinois at Chicago, Chicago, IL, USA
OBJECTIVES: The results of previous studies in examining
various factors inﬂuenced the prescribing of antidepressants have
not been entirely consistent. Some studies, for instance, showed
older patients were more likely to receive antidepressants, while
some showed the opposite. This study aimed to investigate how
patient and physician characteristics that might have inﬂuenced
the prescribing of antidepressants. METHODS: The 1997~2001
National Ambulatory Medical Care Survey (NAMCS) data was
analyzed with a popular data-mining tool–Exhaustive CHAID
classiﬁcation tree. The dependent variable was whether a patient
was prescribed an antidepressant. The candidate explanatory
variables were 13 characteristics associated with the patient or
the physician. From the candidate explanatory variables, the
CHAID algorithm will automatically check both the main and
interaction effects, and select the ones that can best differentiate
the groups with respect to the likelihood of prescribing an 
antidepressant. RESULTS: In total, 113,128 ofﬁce visits were
included. About 6.7% of them were prescribed at least 1 anti-
depressant between 1997 and 2000. Eleven signiﬁcant explana-
tory variables (diagnosis of depression, reporting depressive
symptoms, payment source, duration of visit, patient age, patient
gender, physician specialty, whether the physician was the patient
primary care physician (PCP), new/old patient, solo practice, the
location of the practice, and the region of the practice) and three
interaction effects (physician specialty and solo practice, patient
age and diagnosis of depression, and whether the physician was
the patient PCP and diagnosis of depression) were found by
CHAID. The results showed that for those who were diagnosed
with depression, younger patients were more likely to receive an
antidepressant. In contrast, for those without a diagnosis of
depression, older patients were more likely to receive antide-
pressants. CONCLUSIONS: These 11 explanatory variables
haven inﬂuenced the prescribing of antidepressants. The three
interaction effects detected by CHAID clariﬁed some of the
inconsistencies in the previous studies.
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OBJECTIVES: Beck Depression Index I and II (BDI) and Mood
and Anxiety Symptoms Questionnaire (MASQ) are well-known
instruments for clinical assessment of depression. Our objectives
were to compare measurement properties of BDI-I and II with
MASQ’s depression components and their measurement perfor-
mance with off-target samples. METHODS: Two samples of psy-
chologically healthy college students (sample size of 851 and 433
respectively) were randomly selected to complete BDI-I, MASQ
and BDI-II. Partial credit and rating scale model estimation with
WINSTEPS software were implemented for BDI-I/II and MASQ
respectively. Scale performance criteria included dimensionality,
rating scale functioning, separation and reliability, as well as con-
struct deﬁnition and convergence. RESULTS: All three instru-
ments demonstrated strong measurement properties, although
MASQ provided more coherent rating scale use, better person
and item separations and reliabilities, as well as slightly broader
measurement range. Residual principal components factor analy-
sis of MASQ found positively and negatively worded items
forming a structure that accounted for 15% of variance. This
factor is highly correlated with the measurement depression
dimension and does not present a threat to validity. CONCLU-
SIONS: Certain aspects of item performance in all instruments
should be improved. In particular, misﬁtting items could be
removed or revised and several redundant items dropped. It may
also be necessary to add items that ﬁll gaps left by scale reﬁne-
ment to maintain precision and reliability. There is a general need
to shorten the instruments for better and more efﬁcient depres-
sion measurement.
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OBJECTIVE: Two percent of all children and 4% of all adoles-
cents in the United States have been diagnosed with Major
Depressive Disorder (MDD). Unfortunately, many children and
adolescents who have MDD never receive proper treatment. Of
those who do receive treatment, antidepressants are commonly
utilized. In October, 2004 the US Food and Drug Administration
(FDA) issued a Public Health Advisory to warn that increased
risk of suicidal thoughts and behaviors may be associated with
the use of antidepressant medications, including SSRIs, in chil-
dren and adolescents. Since this warning is based, in part, on 
the hypothesis that the use of SSRIs may increase the risk of 
suicidality (thoughts and behaviors), this review examines how
suicidality has been measured in randomized controlled trials
(RCTs) of SSRI use in children and adolescents with MDD.
METHODS: The tiered search strategy included RCTs published
between January 1, 1985 and October 31, 2004. Three electronic
bibliographic databases (Medline, PsycINFO, and Dissertation
Abstracts) and the Cochrane Libraries were searched for research
articles meeting the deﬁned inclusion criteria for children and
adolescents. RESULTS: Eight randomized controlled trials met
the inclusion criteria. All eight studies had a general recording
of adverse events, but only four utilized one or more formalized
measure(s) of suicidality. Two of the measures consisted of only
one item related to suicidal ideation, and not all measures used
had been previously validated. CONCLUSIONS: No consistent
methods for deﬁning or measuring suicidality were employed
across studies, even those used to rationalize the FDA warning.
Furthermore, when suicidality was measured, only a part of sui-
cidality was formally measured. Future research should utilize
consistent deﬁnitions and validated measurements of suicidality
so that the risks associated with SSRIs in children and adoles-
cents with MDD will be accurately understood and effectively
compared.
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OBJECTIVES: To compare and contrast the Exhaustive CHAID
classiﬁcation tree to forward stepwise LR in explaining the pre-
scribing of antidepressants in terms of identifying explanatory
variables and interaction effects, accuracy, sensitivity, speciﬁ-
city, and Receiver Operating Characteristic (ROC) analysis.
METHODS: Throughout 1997–2001, National Ambulatory
Medical Care Survey (NAMCS) data was used. The dependent
variable was the prescribing of antidepressants and the explana-
tory variables were 13 variables associated with the patient and
physician characteristics. The data was randomly divided by 7 :
3 for training set and test set. The training set was used to train
the Exhaustive CHAID and forward stepwise LR models and the
test set was used to evaluate the performance of both models.
RESULTS: About 6.7% of the 113,128 ofﬁce visits analyzed had
been prescribed at least 1 antidepressant. While the forward step-
wise LR resulted to all 13 explanatory variables as signiﬁcant,
the Exhaustive CHAID identiﬁed 11 explanatory variables and
3 interactions as signiﬁcantly associated with the prescribing of
antidepressants. The Pearson correlation of the predicted logits
from both models was 0.76492 (p < 0.001). At cut point of 0.5,
the classiﬁcation accuracy, sensitivity, and speciﬁcity of Exhaus-
tive CHAID were 0.95, 0.51, and 0.98 respectively, and were
0.95, 0.36, and 0.99 correspondingly for forward stepwise LR.
The area under the ROC curve of Exhaustive CHAID (0.8610)
slightly and signiﬁcantly outperformed that of forward stepwise
LR (0.8507). CONCLUSIONS: The performance of Exhaustive
CHAID was at least as comparable with forward stepwise LR.
In addition, Exhaustive CHAID has the capacity to automati-
cally detect interaction effects without having to specify a priori
the potential interaction terms. The Exhaustive CHAID produces
a more parsimonious model by using fewer variables to explain
the dependent variable. The resulting classiﬁcation tree also 
provides a visually informative structure on how variables are
selected into the model by their relative contributions.
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AMONG PERSONS WITH MAJOR DEPRESSIVE EPISODE AND
ANXIETY
Supina AL1, Johnson J2, Maxwell CJ1, Patten SB1,Williams J1
1University of Calgary, Calgary, AB, Canada; 2University of Alberta,
Edmonton, AB, Canada
OBJECTIVES: Major depressive episodes (MDE) and anxiety
are associated with decreased health-related quality of life
(HRQL). The EQ-5D assesses ﬁve domains, including the single
domain of Anxiety/Depression. Thus, the EQ-5D may be limited
in differentiating among subjects with either or both of MDE
and anxiety disorders. Our objective was to determine the ability
of the EQ-5D to differentiate among persons with MDE or
anxiety alone or in combination, compared with neither.
METHODS: Data were collected in 2003 as part of the Alberta
Mental Health Survey and were obtained through random digit
dialing and computer assisted telephone interviews. MDE and
anxiety were deﬁned by DSM-IV using the Mini International
Neuropsychiatric Interview. HRQL was measured with the 
EQ-5D; responses on the Anxiety/Depression domain were
dichotomized to 1) no problem, or 2) moderate/extreme prob-
lems. Descriptive and multivariate analyses were used to examine
associations between EQ-5D scores and mental health diagnoses.
RESULTS: The average age of the sample (n = 5383) was 40.8
(12.1) years, 61% were female. The prevalence for diagnoses
(and proportion within each group reporting problems on the
Anxiety/Depression domain) were: MDE alone 2.6% (48.6%);
anxiety alone 11.3% (38.7%); MDE and anxiety 5.2% (80.8%);
and neither 80.9% (8.2%), respectively. Compared with subjects
with neither condition, after adjustment for socio-demographic
variables, mean EQ-Index and EQ-VAS scores were signiﬁcantly
lower for subjects with MDE and anxiety (0.70, 64.2), followed
by those with MDE alone (0.83, 70.8) and anxiety alone (0.84,
76.7). CONCLUSIONS: Respondents with MDE or anxiety
alone reported similar burden on the EQ-5D, overall and on the
Anxiety/Depression domain. Comorbid MDE and anxiety is
reﬂected in substantially lower EQ-5D scores. The EQ-5D per-
forms reasonably well as a measure of general mental health, but
more in-depth and speciﬁc measures would be required to iden-
tify and differentiate the impact of isolated mental health con-
ditions on HRQL.
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OBJECTIVES: Depression-free days (DFD) and quality-adjusted
days (QAD) are used to assess the overall effectiveness of anti-
depressants for patients with major depressive disorder (MDD).
Both metrics estimate utility based on fractions from scores on
the Hamilton Rating Scale for Depression (HAM-D). The objec-
tive of this study was to develop a new patient-preference
